Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01364467 · ClinicalTrials.gov registry record · Phase 2

The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study

A Phase 2 study, sponsored by Virginia Commonwealth University.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target

NCT01364467 is a Phase 2 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01364467, a Phase 2 study, has completed, sponsored by Virginia Commonwealth University.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target

Study Summary

This is a 14-day, randomized, placebo-controlled, parallel group, masked clinical trial of oral guaifenesin for the therapy of Chronic Rhinitis (CRS) in 36 children between the ages of 7 and 18 years. The study investigates the effectiveness of guaifenesin in the relief of nasal symptoms in children with CRS using the sinonasal 5 survey (SN-5) in comparison to nasal airway volume, and biophysical properties of nasal secretion. The investigators hypothesize that Guaifenesin use over a period of 14 days improves subjective nasal complaints in pediatric patients with chronic rhinitis and nasal congestion, as measured by the SN-5 survey compared to use of placebo. There will be an observed improvement in nasal volume and cross-sectional area following use of guaifenesin, and nasal secretions will have more favorable mucociliary and sneeze clearability compared to use of placebo.

Interventions

  • DRUG Placebo
  • DRUG Guaifenesin

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2011-05
Est. Completion 2018-03-05
Phase Phase 2

Sponsor

Virginia Commonwealth University

558 total trials

What the Registry Record Tells You About NCT01364467

The ClinicalTrials.gov registry entry for NCT01364467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01364467 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01364467 about?

NCT01364467 is a clinical study titled "The Effect of Oral Guaifenesin on Pediatric Chronic Rhinitis: A Pilot Study". This is a 14-day, randomized, placebo-controlled, parallel group, masked clinical trial of oral guaifenesin for the therapy of Chronic Rhinitis (CRS) in 36 children between the ages of 7 and 18 years. The study investigates the effectiveness of guaifenesin in the relief of nasal symptoms in children...

What is the current status of trial NCT01364467?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2011-05. Estimated completion is 2018-03-05.

What interventions are being tested in trial NCT01364467?

The interventions under investigation include: Placebo (DRUG), Guaifenesin (DRUG).

Who is sponsoring clinical trial NCT01364467?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.